PUBLISHED DATE : Mar 2021 | Pages : 207
Fill out your details & get your free sample
COVID-19 Vaccine Market Size, Share, Trends Analysis Report by Technology (Vector-based, Nucleic acid-based, Protein-based, and Whole Virus); and Geography (APAC, North America, Europe, Latin America, and Middle East & Africa); Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022–2024
207 Pages
61 Tables
76 Charts
5 Regions
20 Countries
27 Companies
2 Market Segment
| Report Attribute | Details |
|---|---|
| MARKET SIZ | USD 5 BILLION (2024) |
| Base Year | 2021 |
| Forecast Year | 2022-2024 |
| Market Segments | Technology (Vector-based, Nucleic acid-based, Protein-based, and Whole Virus) |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, UK, Germany, France, Spain, Russia, Italy, China, India, Japan, South Korea, Australia, Brazil, Mexico, South Africa, Saudi Arabia, Turkey, Egypt, and UAE |
The global COVID-19 vaccine market size is expected to reach USD 5 billion by 2024.
Constant focus by government agencies and several vaccine manufacturers to prevent human and economic losses due to the COVID-19 virus across the world is expected to boost the market's growth. With several vendors implementing new strategies, including combining the phase 1 & 2 clinical trial stages and faster regulatory approvals from health agencies, the availability of vaccine doses across the globe is likely to grow during the forecast period.
In response to the COVID-19 pandemic, there is a rapid expansion of novel COVID-19 vaccines in the pipeline. The role of public-private partnerships is further accelerating the vaccine development process. Increased vaccine development efforts across the world have helped generate a broad pipeline of vaccines and novel delivery mechanisms to achieve global immunization in the expected time. Hence, high investments in COVID-19 vaccine development programs, increased manufacturing capacities, and the establishment of new PPPs driving R&D activities are likely to boost the global COVID-19 vaccine market.
J&J’s non-replicating viral vector vaccine has successfully entered its third phase. Novavax’s Nanoparticle COVID vaccine has demonstrated strong efficacy in the Phase 3 UK trial. Sensing the urgency to curb the COVID-pandemic, several manufacturers have entered into the third phase of the vaccine's clinical trials. Johnson & Johnson (J&J), Novavax, and CanSino Biologics have reported promising results during the third phase. J&J is likely to end the practice of two-dose as the company is about to roll out its easier-to-use, single-dose COVID-19 vaccine.
This research report includes a detailed segmentation by
Protein-based vaccines constitute the highest COVID-19 vaccine market share as they contain the purified pieces of pathogen rather than the whole pathogen to trigger the immune response. In the absence of any significant adverse effect on the human body, these vaccines are likely to observe substantial growth during the forecast period. Novavax, Chinese Academy of Sciences, and GSK/Sanofi are the major manufacturers that have approved protein-based vaccines for emergence use authorization. Protein-based vaccines can be used in patients with compromised immune responses.
Viral-vector-based vaccines account for the second-largest market share. The availability of well-established vaccine manufacturing infrastructure, which can help developing an effective vaccine in a short period, is a significant factor contributing to the growth of viral-based vaccines. Other major factors influencing the growth are high suitability for compromised immune systems patients and a relatively simple manufacturing process. However, a high adverse effect on humans is likely to decrease market growth. Sinovac, Sinopharm, CNBG, Bharat Biotech, Valneva, and Medicago are the major viral-based vaccine manufacturers.
The outbreak of the COVID-19 pandemic was witnessed across the globe. Countries such as the UK, the US, Italy, Spain, India, China were the most affected; however, Middle East and African countries observed a low to moderate occurrence rate. The APAC market dominated the global COVID-19 vaccine market with over 58% share, followed by Europe with 15% and North America with 12%. The Middle East and Africa, and Latin America accounted for 10 % and 6%, respectively. Since the outbreak of the disease in 2019, which eventually was declared a pandemic by the WHO in March 2020, the spread has been thick and fast, swaying country after country and region after region. Most developed regions such as North America and Europe suffered high mortality. While the APAC region witnessed an unprecedented surge in the spread of the infection, the death rate was comparatively low. Several western countries observed a second wave of COVID-19 infection in mid-2020, causing further loss of lives, thereby driving vaccine manufacturers to speed up their efforts. Over 250 vaccine developers across the globe are working on several platforms to produce an effective vaccine. However, most COVID-19 vaccine-related R&D activities are focused on North America, with 46% developers of the confirmed active vaccine candidates compared with 18% in China, 18% in Asia (excluding China) and Australia, and 18% in Europe. Over 50% of vaccines made up to the clinical trial phase are in the North America, Europe, and APAC regions.
AstraZeneca, GlaxoSmithKline, Moderna, Gamaleya, Bharat Biotech, and Pfizer are the major manufacturers of COVID-19 vaccines. Biotechnology and pharmaceutical industries are intensely competitive and are characterized by rapid and significant technological progress in vaccine development. Multiple products have been approved by the USFDA, EU, and other regulatory bodies for emergency use authorization (EUA) worldwide. Many products are manufactured using the latest vaccine platforms in the market.
By Technology
By Geography
Frequently Asked Questions
Which manufacturers are coming up with COVID-19 vaccines in 2021?
Johnson and Johnson, GSK, and Serum Institute of India are the major manufacturing coming out with COVID-19 vaccines by the end of 2021.
What is the size of the COVID-19 vaccine market by 2024?
The global COVID-19 vaccine market is likely to cross over $5 billion by the end of 2024.
Who are the major market players?
AstraZeneca, GlaxoSmithKline, Moderna, Gamaleya, Bharat Biotech, and Pfizer are the major manufacturers of the COVID-19 vaccine.
Which regions are likely to generate the largest revenues in 2021?
APAC, Europe, and North America are expected to the largest revenue by the end of 2021.
What are the major challenges faced by vendors in the distribution of the COVID-19 vaccine?
Shortage of raw materials for vaccine manufacturing, lack of cold storage facilities, absence of skilled manpower, and the dearth of high-capacity production units are the major challenges faced by vendors.
The global COVID-19 vaccine market by revenue is expected to reach USD 5 billion in 2024
The following factors are likely to contribute to the growth of the COVID-19 market during the forecast period:
Base Year: 2021
Forecast Year: 2022–2024
The study considers the COVID-19 vaccine market's present scenario and its market dynamics for the forecast period 2022−2024. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Prominent Vendors
Upcoming Vendors
By Technology
By Geography
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope Of The Study
4.3.1 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
8 Market Opportunities & Trends
8.1 Upcoming COVID-19 Vaccines
8.2 COVID-19 Vaccine Initiatives
8.3 Emergence of Next-Generation Vaccine Platforms
9 Market Growth Enablers
9.1 Faster Regulatory Approvals Of COVID-19 Vaccine
9.2 Rise In Number Of COVID-19 Patients
9.3 Contract Manufacturers Accelerating COVID-19 Vaccine Production
10 Market Restraints
10.1 COVID-19 Vaccine Distribution Among LMICs
10.2 Adverse Events & Negative Impact Of Approved Vaccines
10.3 Low Acceptance Of COVID-19 Vaccine
11 Market Landscape
11.1 Market Overview
11.2 COVID-19 Vaccine Pipeline
11.3 Market Size & Forecast
11.4 COVID-19 Supply Chain
11.5 Role of Contract Manufacturers in Manufacturing COVID-19 Vaccines
11.6 Five Forces Analysis
11.6.1 Threat of New Entrants
11.6.2 Bargaining Power of Suppliers
11.6.3 Bargaining Power of Buyers
11.6.4 Threat of Substitutes
11.6.5 Competitive Rivalry
12 Technology
12.1 Overview
12.2 Vector-Based COVID-19 Vaccine
12.2.1 Overview
12.3 Nucleic Acid-Based COVID-19 Vaccine
12.3.1 Overview
12.4 Protein-Based COVID-19 Vaccine
12.4.1 Overview
12.5 Whole Virus COVID-19 Vaccine
12.5.1 Overview
13 Geography
13.1 Market Snapshot & Growth Engine
13.2 Geographic Overview
14 APAC
14.1 Market Overview
14.2 Market Size & Forecast
14.3 Key Countries
14.3.1 China: Market Size & Forecast
14.3.2 India: Market Size & Forecast
14.3.3 Japan: Market Size & Forecast
14.3.4 South Korea: Market Size & Forecast
14.3.5 Australia: Market Size & Forecast
15 Europe
15.1 Market Overview
15.2 Market Size & Forecast
15.3 Key Countries
15.3.1 UK: Market Size & Forecast
15.3.2 Germany: Market Size & Forecast
15.3.3 Italy: Market Size & Forecast
15.3.4 France: Market Size & Forecast
15.3.5 Russia: Market Size & Forecast
15.3.6 Spain: Market Size & Forecast
16 North America
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 US: Market Size & Forecast
16.3.2 Canada: Market Size & Forecast
17 Middle East & Africa
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 Turkey: Market Size & Forecast
17.3.2 Saudi Arabia: Market Size & Forecast
17.3.3 Egypt: Market Size & Forecast
17.3.4 South Africa: Market Size & Forecast
17.3.5 UAE: Market Size & Forecast
18 Latin America
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Brazil: Market Size & Forecast
18.3.2 Mexico: Market Size & Forecast
19 Competitive Landscape
19.1 Competition Overview
19.1.1 AstraZeneca
19.1.2 Moderna
19.1.3 Gamaleya
19.1.4 Pfizer
19.1.5 Johnson &Johnson
19.1.6 GlaxoSmithKline
19.1.7 Novavax
19.1.8 Bharath Biotech
19.1.9 CureVac
19.1.10 Serum Institute of India
19.1.11 Sinovac
19.1.12 Sinopharm
20 Key Company Profiles
20.1 AstraZeneca
20.1.1 Business Overview
20.1.2 Product Offerings
20.1.3 Key Strategies
20.1.4 Key Strengths
20.1.5 Key Opportunities
20.2 GlaxoSmithKline
20.2.1 Business Overview
20.2.2 Product Offerings
20.2.3 Key Strategies
20.2.4 Key Strengths
20.2.5 Key Opportunities
20.3 Moderna
20.3.1 Business Overview
20.3.2 Product Offerings
20.3.3 Key Strategies
20.3.4 Key Strengths
20.3.5 Key Opportunities
20.4 Gamaleya
20.4.1 Business Overview
20.4.2 Product Offerings
20.4.3 Key Strategies
20.4.4 Key Strengths
20.4.5 Key Opportunities
20.5 Bharat Biotech
20.5.1 Business Overview
20.5.2 Product Offerings
20.5.3 Key Strategies
20.5.4 Key Strengths
20.5.5 Key Opportunities
20.6 Pfizer
20.6.1 Business Overview
20.6.2 Product Offerings
20.6.3 Key Strategies
20.6.4 Key Strengths
20.6.5 Key Opportunities
20.7 Johnson & johnson
20.7.1 Business Overview
20.7.2 Product Offerings
20.7.3 Key Strategies
20.7.4 Key Strengths
20.7.5 Key Opportunities
20.8 BioNTech
20.8.1 Business Overview
20.8.2 Product Offerings
20.8.3 Key Strategies
20.8.4 Key Strengths
20.8.5 Key Opportunities
20.9 CureVac
20.9.1 Business Overview
20.9.2 Product Offerings
20.9.3 Key Strategies
20.9.4 Key Strengths
20.9.5 Key Opportunities
20.10 Serum Institute of India
20.10.1 Business Overview
20.10.2 Product Offerings
20.10.3 Key Strategies
20.10.4 Key Strengths
20.10.5 Key Opportunities
20.11 Novavax
20.11.1 Business Overview
20.11.2 Product Offerings
20.11.3 Key Strategies
20.11.4 Key Strengths
20.11.5 Key Opportunities
20.12 Sinovac
20.12.1 Business Overview
20.12.2 Product Offerings
20.12.3 Key Strategies
20.12.4 Key Strengths
20.12.5 Key Opportunities
20.13 Sinopharm
20.13.1 Business Overview
20.13.2 Product Offerings
20.13.3 Key Strategies
20.13.4 Key Strengths
20.13.5 Key Opportunities
21 Upcoming Vendors
21.1 AnGes
21.1.1 Business Overview
21.2 AIVITABiomedical
21.2.1 Business Overview
21.3 CanSinoBio
21.3.1 Business Overview
21.3.2 Product Offerings
21.4 eubiologics
21.4.1 Business Overview
21.5 Genexine
21.5.1 Business Overview
21.6 GreenLight Bioscience
21.6.1 Business Overview
21.7 Gennova
21.7.1 Business Overview
21.8 Heat Biologics
21.8.1 Business Overview
21.9 INOVIO
21.9.1 Business Overview
21.10 IIBR
21.10.1 Business Overview
21.11 medicago
21.11.1 Business Overview
21.12 Symvivo
21.12.1 Business Overview
21.13 Valneva
21.13.1 Business Overview
21.14 Zydus Cadila
21.14.1 Business Overview
22 Report Summary
22.1 Key Takeaways
22.2 Strategic Recommendations
23 Quantitative Summary
23.1 Market By Geography
23.2 North America
23.3 Europe
23.4 APAC
23.5 Latin America
23.6 Middle East & Africa
24 Appendix
24.1 Abbreviations
List Of Exhibits
Exhibit 1 Global COVID-19 Vaccines Market
Exhibit 2 Market Size Calculation Approach 2021
Exhibit 3 Projected Manufacturing Capacity of Lead Companies Producing COVID-19 Vaccines by End of 2021 (in billions)
Exhibit 4 Impact of Upcoming COVID-19 Vaccine
Exhibit 5 Impact of COVID-19 Vaccine Initiatives
Exhibit 6 Impact of Emergence of Next-Generation Vaccine Platforms
Exhibit 7 Impact of Faster Regulatory Approvals of COVID-19 Vaccine
Exhibit 8 Impact of Rise in Number of COVID-19 Patients
Exhibit 9 COVID-19 Cases in Major Regions
Exhibit 10 Impact of Contract Manufacturers Accelerating COVID-19 Vaccine Production
Exhibit 11 Impact of COVID-19 Vaccine Distribution Among LMICs
Exhibit 12 Income Classification by Confirmed Doses Purchased ($ billions)
Exhibit 13 Impact of Adverse Events & Negative Impact of Approved Vaccines
Exhibit 14 Impact of Low Acceptance of COVID-19 Vaccine
Exhibit 15 People Not Willing to Take COVID-19 Vaccine (% share)
Exhibit 16 COVID-19 Vaccines Under Development by Dosage
Exhibit 17 COVID-19 Vaccines Under Development by Route of Administration
Exhibit 18 Global COVID-19 Vaccines Market 2021–2024 ($ billion)
Exhibit 19 COVID-19 Vaccine Logistics & Distribution
Exhibit 20 COVID-19 Vaccine Development 2021 (% share)
Exhibit 21 Five Forces Analysis 2021
Exhibit 22 Incremental Growth by Geography 2021 & 2024
Exhibit 23 Global COVID-19 Vaccines Market by Geography
Exhibit 24 Global COVID-19 Vaccines Market 2021- 2024 ($ million)
Exhibit 25 Global COVID-19 Vaccines Market 2021- 2024 (% share)
Exhibit 26 Production Capabilities of COVID-19 Vaccine Candidates Per Country (millions)
Exhibit 27 Income Classification by Confirmed Number of Doses Purchased by Country (Doses in billions)
Exhibit 28 APAC COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth
Exhibit 29 COVID-19 Vaccines Market in APAC 2021–2024 ($ billion)
Exhibit 30 Incremental Growth in APAC 2021 & 2024
Exhibit 31 COVID-19 Vaccines Market in China 2021–2024 ($ million)
Exhibit 32 COVID-19 Vaccines Market in India 2021–2024 ($ million)
Exhibit 33 COVID-19 Vaccines Market in Japan 2021–2024 ($ million)
Exhibit 34 COVID-19 Vaccines Market in South Korea 2021–2024 ($ million)
Exhibit 35 COVID-19 Vaccines Market in Australia 2021–2024 ($ million)
Exhibit 36 Europe COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth
Exhibit 37 COVID-19 Vaccines Market in Europe 2021–2024 ($ billion)
Exhibit 38 Incremental Growth in Europe 2021 & 2024
Exhibit 39 COVID-19 Vaccines Market in UK 2021–2024 ($ million)
Exhibit 40 COVID-19 Vaccines Market in Germany 2021–2024 ($ million)
Exhibit 41 COVID-19 Vaccines Market in Italy 2021–2024 ($ million)
Exhibit 42 COVID-19 Vaccines Market in France 2021–2024 ($ million)
Exhibit 43 COVID-19 Vaccines Market in Russia 2021–2024 ($ million)
Exhibit 44 COVID-19 Vaccines Market in Spain 2021–2024 ($ million)
Exhibit 45 North America COVID-19 Vaccine Market: Incremental Growth vs. Absolute Growth
Exhibit 46 COVID-19 Vaccine Developers in North America
Exhibit 47 COVID-19 Vaccines Market in North America 2021–2024 ($ billion)
Exhibit 48 Incremental Growth in North America 2021 & 2024
Exhibit 49 COVID-19 Vaccines Market in US 2021–2024 ($ million)
Exhibit 50 COVID-19 Vaccines Market in Canada 2021–2024 ($ million)
Exhibit 51 Middle East & Africa COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth
Exhibit 52 COVID-19 Vaccines Market in Middle East & Africa 2021–2024 ($ billion)
Exhibit 53 Incremental Growth in Middle East & Africa 2021 & 2024
Exhibit 54 COVID-19 Vaccines Market in Turkey 2021–2024 ($ million)
Exhibit 55 COVID-19 Vaccines Market in Saudi Arabia 2021–2024 ($ million)
Exhibit 56 COVID-19 Vaccines Market in Egypt 2021–2024 ($ million)
Exhibit 57 COVID-19 Vaccines Market in South Africa 2021–2024 ($ million)
Exhibit 58 COVID-19 Vaccines Market in UAE 2021–2024 ($ million)
Exhibit 59 Latin America COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth
Exhibit 60 COVID-19 Vaccine Market in Latin America 2021–2024 ($ billion)
Exhibit 61 Incremental Growth in Latin America 2021 & 2024
Exhibit 62 COVID-19 Vaccines Market in Brazil 2021–2024 ($ million)
Exhibit 63 COVID-19 Vaccines Market in Mexico 2021–2024 ($ million)
Exhibit 64 AstraZeneca Revenue 2017-2019 ($million)
Exhibit 65 AstraZeneca Research & Development Expenditure ($ million)
Exhibit 66 GlaxoSmithKline Revenue 2017-19 (billions)
Exhibit 67 Moderna Revenue 2017-2019 ($ million)
Exhibit 68 Moderna Research & Development Expenditure ($ million)
Exhibit 69 Pfizer Revenue 2017- 2019 ($ billion)
Exhibit 70 Pfizer Research & Development 2017- 2019 ($ billion)
Exhibit 71 Johnson & Johnson Revenue 2017- 2019 ($ million)
Exhibit 72 Johnson & Johnson Research & Development 2017- 2019 ($ million)
Exhibit 73 BioNTech Revenue 2017- 2019 (million)
Exhibit 74 BioNTech Research & Development 2017- 2019 ($ million)
Exhibit 75 Novavax Revenue 2017-2019 (million)
Exhibit 76 Novavax Research &Development Expenditure 2017-2019 (million)
List Of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2013−2020
Table 3 Up-Coming COVID-19 Vaccines
Table 4 Comparison of Up-Coming COVID-19 Vaccine Platforms
Table 5 COVID-19 Cases in Top Ten Countries
Table 6 COVID-19 Vaccines EUA Approved as of Mid of 2021 January
Table 7 COVID-19 Vaccines Approved for Use in Various Countries
Table 8 COVID-19 Candidates in Clinical Phase Based on Vaccines Types
Table 9 List of COVID-19 Vaccines Under Phase II & III Clinical Trial
Table 10 List of COVID-19 Vaccines Under Phase I & II Clinical Trial
Table 11 List of COVID-19 Vaccines Under Phase I & Pre-Clinical Trial
Table 12 Key companies & CMOs Agreements for COVID-19 Vaccine (millions)
Table 13 EUA-Approved COVID-19 Vaccines
Table 14 COVID-19 Vaccines Based on Vector Platform Under Development
Table 15 COVID-19 Vaccines Based on Nucleic Acid Platform Under Development
Table 16 COVID-19 Vaccines Based on Protein Platform Under Development
Table 17 COVID-19 Vaccines Based on Whole Virus Platform Under Development
Table 18 Regional Confirmed COVID-19 Cases WHO (as of 2021 February)
Table 19 Countries with Highest COVID-19 Cases & Deaths
Table 20 List of Agreements Signed for COVID-19 Vaccines
Table 21 Approved Vaccines for COVID-19 in UK
Table 22 UK Agreement with Companies for COVID-19 Vaccine (million)
Table 23 List of Agreements Signed for COVID-19 Vaccines
Table 24 Approved Vaccines for COVID-19 in US
Table 25 US Agreement with Companies for COVID-19 Vaccine (million)
Table 26 List of Agreements Signed for COVID-19 Vaccines
Table 27 List of Agreements Signed for COVID-19 Vaccines.
Table 28 List of Agreements Signed for COVID-19 Vaccines with AstraZeneca
Table 29 List of Agreements Signed for COVID-19 Vaccines with Moderna
Table 30 List of Agreements Signed for COVID-19 Vaccines with Pfizer
Table 31 List of Agreements Signed for COVID-19 Vaccines with Johnson & Johnson
Table 32 List of Agreements Signed for COVID-19 Vaccines with GSK
Table 33 List of Agreements Signed for COVID-19 Vaccines with Novavax
Table 34 List of Agreements Signed for COVID-19 Vaccines with CureVac
Table 35 List of Agreements Signed for COVID-19 Vaccines with SinoVac
Table 36 AstraZeneca: Major Product Offerings
Table 37 GlaxoSmithKline: Major Product Offerings
Table 38 Moderna: Major Product Offerings
Table 39 Gamaleya: Major Product Offerings
Table 40 Bharat Biotech: Major Product Offerings
Table 41 Pfizer: Major Product Offerings
Table 42 Johnson & Johnson: Major Product Offerings
Table 43 BioNTech: Major Product Offerings
Table 44 CureVac: Major Product Offerings
Table 45 Serum Institute of India: Major Product Offerings
Table 46 Novavax: Major Product Offerings
Table 47 Sinovac: Major Product Offerings
Table 48 Sinopharm: Major Product Offerings
Table 49 CanSinoBio: Major Product Offerings
Table 50 Global COVID-19 Vaccines Market by Geography 2021−2024 ($ million)
Table 51 Global COVID-19 Vaccines Market by Geography 2021−2024 (%)
Table 52 North America COVID-19 Vaccines Market 2021−2024 ($ million)
Table 53 North America COVID-19 Vaccines Market 2021−2024 (%)
Table 54 Europe COVID-19 Vaccines Market 2021−2024 ($ million)
Table 55 Europe COVID-19 Vaccines Market 2021−2024 (%)
Table 56 APAC COVID-19 Vaccines Market 2021−2024 ($ million)
Table 57 APAC COVID-19 Vaccines Market 2021−2024 (%)
Table 58 Latin America COVID-19 Vaccines Market 2021−2024 ($ million)
Table 59 Latin America COVID-19 Vaccines Market 2021−2024 (%)
Table 60 Middle East & Africa COVID-19 Vaccines Market 2021−2024 ($ million)
Table 61 Middle East & Africa COVID-19 Vaccines Market 2021−2024 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
